NEWS

November 2, 2026

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

August 14, 2026

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

July 14, 2026

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

July 1, 2026

BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

April 22, 2026

HealthCare Royalty Announces Royalty Monetization Agreement for Modeyso® Commercial Royalties

April 6, 2026

Apnimed Secures Up to $150 Million in Debt Financing with HealthCare Royalty Partners to Support Planned AD109 Commercial Launch

April 2, 2026

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

March 3, 2026

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

October 31, 2025

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

August 7, 2025

Duke Professor Reinvests Royalties into New Research